Targeting of myeloid-derived suppressor cells by all-trans retinoic acid as host-directed therapy for human tuberculosis
- PMID: 33865151
- PMCID: PMC8493473
- DOI: 10.1016/j.cellimm.2021.104359
Targeting of myeloid-derived suppressor cells by all-trans retinoic acid as host-directed therapy for human tuberculosis
Abstract
Conventional anti-tuberculosis (TB) therapies comprise lengthy antibiotic treatment regimens, exacerbated by multi-drug resistant and extensively drug resistant mycobacterial strains. We assessed the ability of all-trans retinoic acid (ATRA), as repurposed compound serving as host-directed therapy (HDT), to counteract the suppressive effects of myeloid-derived suppressor cells (MDSCs) obtained from active TB cases (untreated or during week one of treatment) on T-cell responsiveness. We show for the first time that MDSCs suppress non-specific T-cell activation and production of interleukin (IL)-2, IL-4, IL-13 and GM-CSF via contact-dependent mechanisms. ATRA treatment decreases MDSC frequency, but fails to mature MDSCs to non-suppressive, terminally differentiated myeloid cells and does not restore T-cell function or cytokine production in the presence of MDSCs. The impact of ATRA treatment on improved immunity, using the concentration tested here, is likely to be minimal, but further identification and development of MDSC-targeting TB host-directed therapies are warranted.
Keywords: All-trans retinoic acid; Host-directed therapies; Mycobacterium tuberculosis; Myeloid-derived suppressor cells; Tuberculosis.
Copyright © 2021 The Author(s). Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Figures








Similar articles
-
Myeloid-Derived Suppressor Cells Mediate T Cell Dysfunction in Nonhuman Primate TB Granulomas.mBio. 2021 Dec 21;12(6):e0318921. doi: 10.1128/mbio.03189-21. Epub 2021 Dec 14. mBio. 2021. PMID: 34903057 Free PMC article.
-
The Frequency and Effect of Granulocytic Myeloid-Derived Suppressor Cells on Mycobacterial Survival in Patients With Tuberculosis: A Preliminary Report.Front Immunol. 2021 Jun 1;12:676679. doi: 10.3389/fimmu.2021.676679. eCollection 2021. Front Immunol. 2021. PMID: 34149712 Free PMC article.
-
Sildenafil, a Type-5 Phosphodiesterase Inhibitor, Fails to Reverse Myeloid-Derived Suppressor Cell-Mediated T Cell Suppression in Cells Isolated From Tuberculosis Patients.Front Immunol. 2022 Jul 22;13:883886. doi: 10.3389/fimmu.2022.883886. eCollection 2022. Front Immunol. 2022. PMID: 35935981 Free PMC article.
-
Myeloid-Derived Suppressor Cells as Target of Phosphodiesterase-5 Inhibitors in Host-Directed Therapeutics for Tuberculosis.Front Immunol. 2020 Mar 25;11:451. doi: 10.3389/fimmu.2020.00451. eCollection 2020. Front Immunol. 2020. PMID: 32269568 Free PMC article. Review.
-
Mycobacterium tuberculosis and myeloid-derived suppressor cells: Insights into caveolin rich lipid rafts.EBioMedicine. 2020 Mar;53:102670. doi: 10.1016/j.ebiom.2020.102670. Epub 2020 Feb 26. EBioMedicine. 2020. PMID: 32113158 Free PMC article. Review.
Cited by
-
The immunomodulatory role of all-trans retinoic acid in tumor microenvironment.Clin Exp Med. 2023 Jul;23(3):591-606. doi: 10.1007/s10238-022-00860-x. Epub 2022 Jul 13. Clin Exp Med. 2023. PMID: 35829844 Review.
-
Targeted Gene Expression Profiling of Human Myeloid Cells From Blood and Lung Compartments of Patients With Tuberculosis and Other Lung Diseases.Front Immunol. 2022 Mar 8;13:839747. doi: 10.3389/fimmu.2022.839747. eCollection 2022. Front Immunol. 2022. PMID: 35356003 Free PMC article.
-
Suppressive myeloid cells in SARS-CoV-2 and Mycobacterium tuberculosis co-infection.Front Immunol. 2023 Jul 20;14:1222911. doi: 10.3389/fimmu.2023.1222911. eCollection 2023. Front Immunol. 2023. PMID: 37545508 Free PMC article.
-
All trans retinoic acid as a host-directed immunotherapy for tuberculosis.Curr Res Immunol. 2022 Mar 30;3:54-72. doi: 10.1016/j.crimmu.2022.03.003. eCollection 2022. Curr Res Immunol. 2022. PMID: 35496824 Free PMC article. Review.
-
Myeloid-Derived Suppressor Cells Mediate T Cell Dysfunction in Nonhuman Primate TB Granulomas.mBio. 2021 Dec 21;12(6):e0318921. doi: 10.1128/mbio.03189-21. Epub 2021 Dec 14. mBio. 2021. PMID: 34903057 Free PMC article.
References
-
- World Health Organization, Global tuberculosis report 2018. 2018.
-
- “WHO | Guidelines for treatment of drug-susceptible tuberculosis and patient care (2017 update).” http://www.who.int/tb/publications/2017/dstb_guidance_2017/en/ (accessed Feb. 13, 2018).
-
- Guernsey BG, Alexander MR, Tuberculosis: review of treatment failure, relapse and drug resistance, Am. J. Hosp. Pharm. 35 (6) (Jun. 1978) 690–698. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources